Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments
U. Keilholz(Franklin University), Alexander M.M. Eggermont(University Medical Center Utrecht), G. Mooser(Goethe University Frankfurt), Dirk Schadendorf(National Center for Tumor Diseases), Cornelis J.A. Punt(Utrecht University), Peter Martus(University of Tübingen), Josef Koller(University of Salzburg), D. Liénard, Christiane Voit(Humboldt-Universität zu Berlin), Wim H.J. Kruit(Erasmus MC), R. Dummer(University of Zurich)
Cited by 57
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k